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AbstrAct:
Malignant peripheral nerve sheath tumours (MPNST) are rare, hereditary cancers 
associated with neurofibromatosis type I. MPNSTs lack effective treatment options as 
they often resist chemotherapies and have high rates of disease recurrence. Aurora 
kinase A (AURKA) is an emerging target in cancer and an aurora kinase inhibitor (AKI), 
termed MLN8237, shows promise against MPNST cell lines in vitro and in vivo. Here, 
we test MLN8237 against two primary human MPNST grown in vivo as xenotransplants 
and find that treatment results in tumour cells exiting the cell cycle and undergoing 
endoreduplication, which cumulates in stabilized disease. Targeted therapies can 
often fail in the clinic due to insufficient knowledge about factors that determine 
tumour susceptibilities, so we turned to three MPNST cell-lines to further study and 
modulate the cellular responses to AKI. We find that the sensitivity of cell-lines with 
amplification of AURKA depends upon the activity of the kinase, which correlates with 
the expression of the regulatory gene products TPX2 and HMMR/RHAMM. Silencing of 
HMMR/RHAMM, but not TPX2, augments AURKA activity and sensitizes MPNST cells to 
AKI. Furthermore, we find that AURKA activity is critical to the propagation and self-
renewal of sphere-enriched MPNST cancer stem-like cells. AKI treatment significantly 
reduces the formation of spheroids, attenuates the self-renewal of spheroid forming 
cells, and promotes their differentiation. Moreover, silencing of HMMR/RHAMM is 
sufficient to endow MPNST cells with an ability to form and maintain sphere culture.  
Collectively, our data indicate that AURKA is a rationale therapeutic target for MPNST 
and tumour cell responses to AKI, which include differentiation, are modulated by 
the abundance of HMMR/RHAMM. 
IntroductIon
Neurofibromatosis type I is an autosomal dominant, 
tumour predisposition syndrome [1]. The disease affects 
about 1 in 3000 young adults and causes the occurrence 
of benign dermal and plexiform tumours. Approximately 
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8-13% of affected individuals will develop malignant 
peripheral nerve sheath tumours (MPNSTs) in their 
lifetime [2]. Sporadic MPNST are rare in the general 
population but account for approximately half of 
diagnosed MPNST cases [3]. Both sporadic and NF1-
associated MPNST are difficult to treat owing to their 
resistance to chemotherapy and frequent deep seated 
location in the body, which results in 5-year survival rates 
in the range of 20-50% [2-4].
The molecular mechanisms underlying the 
progression of MPNSTs remain unclear, which limits 
the discovery and application of new targeted therapies. 
Patel and colleagues identified Aurora kinase A 
(AURKA) as a candidate target for MPNST therapy 
by first modeling the disease in an animal model, 
identifying frequent amplification of AURKA in human 
tumours, and then treating MPNST cell-lines grown 
in vitro and as xenotransplants in vivo with an AURKA 
specific inhibitor, termed MLN8237 [5].  AURKA is an 
oncogenic kinase that enables mitotic spindle assembly 
[6], and aurora kinase A inhibitors (AKI) often induce a 
G2/M cell cycle arrest followed by apoptosis in cancer 
cell lines grown in vitro and in vivo  [7, 8]. Inhibitors 
of Aurora kinase B (AURKB) are also effective anti-
mitotic drugs, which often  induce mitotic failure and 
endoreduplication [8]. Treatment of an MPNST cell-line 
with MLN8237 stabilized the cell-line’s growth in vivo 
and induced endoreduplication and senescence in vitro 
[5]. Optimal application of these emerging therapies will 
require a better understanding and prediction of MPNST 
susceptibilities and tumour cell responses.
The examination of copy number variants in human, 
primary dermal or plexiform neurofibromas and MPNSTs 
of differing grades provides an additional link between 
disease progression and the AURKA signalling pathway. 
In approximately half of the high-grade tumours and not 
in low-grade MPNSTs or neurofibromas, hemizygous 
deletion of the hyaluronan mediated motility receptor 
(HMMR) gene was reported [9]. The HMMR gene encodes 
a multifunctional protein (RHAMM) that enables mitotic 
spindle assembly [10] and may attenuate the activation 
of AURKA [11], which relies upon a heterodimeric 
complex with targeting protein for XKLP2 (TPX2) [12]. 
As RHAMM binds TPX2 [13, 14], the hemizygous loss 
of HMMR/RHAMM that is often associated with the 
progression of MPNSTs may release TPX2, activate 
AURKA, and provide a growth advantage.  Indeed, 
both AURKA (20q13.2) and TPX2 (20q11.2) lie within 
chromosomal regions that are frequently amplified in 
sporadic MPNSTs [15, 16]. Taken together, these genomic 
imbalances may oncogene-addict high-grade MPNSTs to 
AURKA activity and sensitize them to the treatment with 
AKIs.
AURKA also regulates non-mitotic events, such as 
apicobasal polarization of epithelia [11], cilia resorption 
[17], and embryonic stem cell fate [18, 19]. In mouse 
embryonic stem cells (mESCs), AURKA is essential 
for maintenance of stem cell populations and silencing 
AURKA or treatment with AKI was sufficient to drive their 
differentiation through mesoderm and ectoderm lineages 
[18]. Thus, AKI may have effects on non-mitotic processes 
in tumour cells, such as the determination of cell fate and 
differentiation.
Here, we propose that AURKA represents a rational 
therapeutic target for MPNSTs and that the sensitivity 
of these tumours to AKI may be regulated by gene 
dosage and expression of HMMR/RHAMM. We find that 
treatment with an AKI efficiently stabilizes the growth of 
two primary human MPNSTs grown as xenografts in vivo. 
The sensitivity of immortalized MPNST cell-lines to this 
class of drugs relies in part on the activity of AURKA, 
which can be modified by targeted silencing of key 
kinase regulators, such as TPX2 and HMMR/ RHAMM. 
Treatment with MLN8237 also engages a differentiation 
program in sphere-enriched MPNST cells that impairs 
their self-renewal and favours differentiation with 
expression of neuron-specific microtubule architecture.
results
Aurora kinase inhibition is an encouraging 
preclinical treatment for human MPnst
A preclinical study of MLN8237 has shown 
efficacy against an immortalized MPNST cell-line that 
was grown in vitro and as a xenotransplant in vivo [5]. 
To build on these findings and test the efficacy of this 
new putative therapy against primary human MPNSTs, 
we treated two human tumours grown as explants in 
vivo (Castellsagué et al., manuscript under preparation). 
One sporadic (SP-MPNST) and one hereditary (NF1-
MPNST) primary, human MPNST were separately 
transplanted orthotopically and expanded in the flank of 
NOD-SCID mice (n= 44 and 39, respectively) to a size of 
2000 mm3, randomized, and treated by oral gavage with 
vehicle control or 30 mg/kg/day MLN8237 for a period 
of four weeks, which is a dosing regimen based upon the 
published in vivo pharmacodynamics for the drug [7]. 
Treatment of animals with MLN8237 resulted in stabilized 
disease for tumour explants from both patients, as opposed 
to the linear expansion of tumour volumes in the vehicle 
treated cohorts (SP-MPNST, p <0.0001; NF1-MPNST, 
p= 0.0011) (Fig 1A,B). Once the dosing schedule was 
completed, tumours were excised and weighed. Consistent 
with the caliper measurements, treatment with MLN8237 
resulted in tumour masses that were significantly lower in 
both the NF1-MPNST and SP-MPNST explants (p<0.01) 
compared to those of vehicle treated tumours (Fig 1A,B).
For insight into the mechanisms through which 
MLN8237 stabilized tumour growth, we examined the 
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Figure 1: Mln8237 is effective against primary MPnsts grown as xenotransplants in vivo A. Sporadic MPNST tumours 
were orthotopically transplanted into NOD/SCID mice and allowed to grow to 2000 mm3 before treatment of 30mg/kg MLN8237 or vehicle 
was delivered daily. Treatment with MLN8237 resulted in stable disease after 2 weeks treatment, as determined by calliper measurements 
of tumour volumes, n=30 MLN8237 treated and n=14 for vehicle treated, *p<0.01, error bars = SD. Representative images of SP-MPNST 
tumours after 28 days of MLN8237 treatment or vehicle control are shown and treatment with the AKI resulted in significant reduction in 
tumour weight (quantitation on the right) (*p<0.01, Error bars = SD).B. NF1-MPNST tumours also show significantly stabilized tumour 
volumes and reduced tumour weight in the MLN8237 treated tumours compared to the vehicle controls. Vehicle treated mice, n=18, 
MLN8237 treated mice, n=21, error bars = SD. C. After 28 days of treatment, SP-MPNST tumour sections were stained for Ki-67 and DAPI. 
Ki-67 staining was significantly decreased in treated tumours suggesting that these cells have exited the cell cycle. Furthermore, there was a 
significant increase in multi-nucleate cells in treated tumours suggesting that cells are undergoing G2/M arrests and endoreduplication post 
treatment. *p<0.01, error bars = SD. Images are taken at 20x magnification.
Oncotarget 2013; 4: 80-9383www.impactjournals.com/oncotarget
excised SP-MPNSTs by immunohistochemistry and found 
evidence that MLN8237 causes tumour cells to exit the 
cell cycle and/or undergo endoreduplication. MLN8237-
treated tumours contained significantly fewer Ki67positive 
cells than the vehicle treated controls (Fig 1C) while the 
fraction of polyploid cells, as measured through the DAPI 
counterstain, was increased within the treated tumour cells 
(Fig 1C).
Figure 2: Inhibition of AurKA attenuates the growth of MPnst cell-lines in vitro. A. Cell lysates collected from S462, 2884 
and 2885 cell lines show equivalent AURKA expression in S462 and 2884 cells lines. Furthermore, these cells lines undergo equivalent 
growth while 2885 cells experience slow proliferation. Seeding densities for S462 and 2884 were modified to enable equivalent proliferation. 
Cell viability was measured by MTT assays over a 4 day period. B. Immunoblot analysis of AURKA expression in lysates from untreated 
S462 cells and those treated with scrambled or AURKA targeted siRNA at 48 hours post transfection reveal specific reduction of AURKA. 
β-actin serves as a loading control. Cell viability is decreased in a dose dependent manner in cells treated with siRNA targeting AURKA 
relative to untreated cells and those cells treated with scrambled siRNA (right). Plotted siAurora values are  obtained from four redundant 
siRNA targeting AURKA. Error bars = SEM, n=5 replicate experiments. C. Treatment of MPNST cells with three inhibitors to Aurora 
kinases, MLN8237, VX680 and C1368, reveals marked and dose-dependent reduction in cell viability as measured by MTT after 72 hours 
of treatment. Error bars = SEM, n=3 replicate experiments.
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Immortalized MPnst cell-lines differ in their 
sensitivity to aurora kinase inhibitors (AKI)
To examine MPNST cellular responses to 
MLN8237 in greater detail, we studied three established 
and immortalized MPNST cell-lines. In two of the cell-
lines (S462 and 2884), the expression of AURKA and 
the kinetics of growth in vitro were equivalent (Fig. 2A). 
The 2885 cell-line, however, was poorly proliferative and 
lysates from these cells contained negligible levels of 
AURKA (Fig. 2A). When the expression of AURKA was 
silenced in S462 cells through transfection of four distinct 
siRNA constructs, cell survival was significantly impacted 
and proportional to the degree of AURKA silencing 
achieved by the various siRNA constructs, which implied 
a dose-response between AURKA abundance and cell 
growth rate or viability (Fig. 2B). We obtained three AKIs 
from commercial sources and tested the ability of each 
AKI to reduce kinase activity. Lysates from S462 cells 
Figure 3: Gene dose alterations in tPX2 and rHAMM account for the differential AurKA activity in MPnst cell-
lines. A. Augmented AURKA activity is detected in S462 cell lysates as measured by immunoblot detection of pS10-Histone H3B and 
pT288-AURKA. Apart from an increased level of RHAMM expression in 2884, levels of the unphosphorylated proteins are relatively 
constant. β-actin serves as a loading control. B. Comparative genomic hybridization of genomic DNA from S462, 2884 and 2885 MPNST 
cell lines identify copy number gains of 20q in S462 and 2884 cells, and a gain of 5q33.2-qter in 2884 cells. C. Quantitative PCR confirms 
increased gene dosage of TPX2, but decreased HMMR, in S462 relative to 2884 cells. Error bars =SD, n=3. D. Gene dosage translates 
to different levels of mRNA for TPX2 and RHAMM as detected by qRT-PCR in S462 relative to 2884 cells. Error bars=SD, n=3. E. 
Representative blots for protein expression of AURKA, TPX2 and RHAMM as detected in cell lysates from S462 and 2884 cell-lines by 
IR labelled antibodies. Consistent with the genomic and message levels, S462 cells contain a marked increase in TPX2 expression and a 
reduced expression of RHAMM relative to 2884 cells. 
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treated with varying concentrations of AKI showed dose 
dependent reduction of pRHAMM (Fig S1A). This was 
confirmed with immunofluorescence analysis of the auto-
activated kinase (p-AURKA) [12] and two downstream 
substrates (pRHAMM and p-histone H3) [11, 20] (Fig 
S1B). Each of the MPNST cell-lines was then separately 
treated with each AKI. Following 72 hours of treatment 
with MLN8237, the survival of each MPNST cell-line in 
vitro was reduced significantly (Fig. 2C). However, the 
sensitivity of the cell-lines did not completely align with 
the levels of AURKA expression, as would be predicted 
from the results of the siRNA experiments.
The 2885 cell-line resisted MLN8237 treatment and 
required 400-725 fold higher concentrations to inhibit 50% 
of cellular growth (IC-50) (Fig. 2C), which is consistent 
with the negligible expression of AURKA in this cell-line. 
Despite equivalent growth rates and AURKA abundance 
in 2884 and S462 cells, however, the cellular responses 
to MLN8237 were significantly different (p=0.02) with 
S462 being the more sensitive (Fig. 2C). We found that 
S462 cells were also 2.2 – 9.2 fold more sensitive to the 
pan-Aurora inhibitors VX680 (IC-50- 2884, 387 ±47 nM; 
S462, 42 ±10 nM) and C1368 (IC-50- 2884, 2925 ±135 
nM; S462, 1302 ±264 nM) (Fig. 2C), which implied that 
factors intrinsic to these cell-lines may influence their 
responses to AKI.
Figure 4: rHAMM depletion increases AurKA activity and sensitivity to AKI in 2884 cells. A. TPX2 was stably knocked 
down in S462 cells using shRNA mediated silencing of either TPX2 or a control non-hairpin (NHP) construct. β-actin served as a loading 
control. B. shTPX2 S462 cells experienced no significant differences in IC-50 to MLN8237 compared to NHP cells, error bars = SD, n=3. 
C. RHAMM was knocked down in 2884 cells with a similar shRNA expression system. Two redundant shRNAs were used, shR1 and shR2. 
β-actin served as a loading control. D. shR1 and shR2 cells experienced a 2 fold decrease in IC-50 in response to MLN8237 treatment 
compared to NHP cells, *p value<0.05, error bars = SD, n=3. E. Representative images of NHP and shR1 cells at metaphase stained 
for AURKA and pAURKA-T288. Scale bars = 5µm. Quantitation of fluorescent intensity of spindle poles was done using FV10-ASW 
software, *p value <0.05, error bars = SD. 
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Genomic imbalances in HMMR/rHAMM and 
tPX2 regulate AurKA activity and the sensitivity 
of MPnst cells to AKIs
We postulated that the sensitivity of the S462 
and 2884 cell-lines to MLN8237 may reflect different 
levels of kinase activity, rather than AURKA abundance. 
Consistently, AURKA-mediated phosphorylation events 
were augmented in S462 cells, while the absolute levels 
of the substrate proteins remained relatively constant 
Figure 5: AKI treatment results in growth arrest, apoptosis, polyploidy and cellular senescence in MPnst cell lines. 
A. Treatment of S462 and 2884 cells with AKI for 48 hours resulted in low levels of apoptosis as detected by Annexin V staining by high 
content cell screening. Representative images are shown with non-viable, membrane permeable cells counter stained with propidium iodide 
(PI). B. Quantitation of cellular responses to AKI or vehicle treatments, *p value <0.05, error bars = SD, n=3 for apoptosis measurements, 
n=3 for polyploidy and n=4 for senescence quantitation. C. S462 and 2884 cells were exposed to AKIs, or vehicle control, and changes 
in the nuclear content of treated cells was detected by PI staining and FACS analysis. S462 cells exposed to AKIs display larger G2/M 
and 8N fractions, indicative of an endoreduplication phenotype. Representative images of cells stained with DAPI are shown above the 
FACS profiles to illustrate the multi-nucleate phenotypes. D. Treatment of S462 cells with AKIs at IC-50 concentrations for 72 hours 
induces senescence activated β-gal expression in comparison to DMSO treated cells. Representative images were taken on an Axiovert 40 
microscope (Zeiss).
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(Fig 3A). So, we screened genomic DNA from each of 
the MPNST cell-lines on a high density oligonucleotide 
a-CGH platform for insight into a putative mechanism that 
accounts for the elevated kinase activity in S462 cells.
The 2885 cell-line displayed a relatively diploid 
genome, however, we identified copy number variation 
in the region surrounding AURKA in 2884 and S462 
cells (Fig. S2A, B). In S462 cells, the region surrounding 
TPX2 (20q11.2) was also amplified (Fig 3B). While in 
2884 cells, the region surrounding HMMR/RHAMM 
(5q33.2-qter) was amplified (Fig 3B). These genomic 
imbalances implied that the S462 cell-line may express 
more TPX2, a protein that activates AURKA [12], and 
less RHAMM, a protein that sequesters TPX2 [11], and 
these imbalances may enhance AURKA activity. With 
quantitative genomic PCR, we confirmed the amplification 
of TPX2 and HMMR/RHAMM in 2884 and S462 cells, 
respectively (Fig. 3C). Moreover, quantitative RT-PCR 
(Fig 3D) and quantitative immunoblot analysis (Fig. 3E) 
showed that the respective gene products were expressed 
in these cell-lines proportionate to the underlying genomic 
amplifications.
To investigate whether altering the expression 
of TPX2 or HMMR/RHAMM is sufficient to modify 
MPNST cellular responses to AKI, we established stable 
S462 and 2884 sub-lines that express shRNA targeting 
TPX2 or HMMR/RHAMM, respectively, as well as a 
non-hairpin (NHP) shRNA control. The growth kinetics 
for sub-lines did not differ significantly to NHP controls 
(Fig S3A, C). We silenced TPX2 within S462 cells and, 
after drug selection, reduced TPX2 protein abundance 
by approximately 40% (Fig. 4A). However, the reduced 
expression of TPX2 did not alter the IC-50 for MLN8237 
(Fig 4B) or VX680 (Fig S3B). Next, we silenced HMMR/ 
RHAMM within 2884 cells with redundant constructs 
(shR1 and shR2) and achieved stable reduction of 
approximately 65% of RHAMM protein after drug 
selection (Fig. 4C). The IC-50 for MLN8237 (Fig 4D) 
and VX680 (Fig S3C) were significantly reduced in sub-
lines in which HMMR/RHAMM was silenced. Moreover, 
the levels of AURKA and p-AURKA immunofluorescence 
intensity were both augmented at spindle poles in mitotic 
2884 cells with stable shRNA-mediated silencing of 
RHAMM (Fig. 4E). These findings suggest that silencing 
of HMMR/RHAMM augments AURKA activity and 
sensitizes MPNST cells to AKI.
We sought to identify and modulate the responsible 
pathways behind the cytostatic effects of MLN8237 on 
MPNST cell-lines and focused our initial investigations 
on pathways that are frequently altered in cells treated 
with AKI, such as apoptotic cell death, arrest at the 
G2-M transition, endoreduplication, and replicative 
senescence [8]. Through high-content analysis of nuclei 
that stained positive for annexin V (marker for early 
apoptosis) but not for propidium iodide (PI, marker for 
necrotic death), we found that after 48 or 72 hours (not 
shown) of MLN8237 treatment approximately 10% of 
cells were apoptotic regardless of the MPNST cell-line 
examined (Fig. 5A and 5B). Similar levels of apoptosis 
were also seen with exposure to VX680, which suggested 
that this cytostatic pathway may not account for the 
differential susceptibility of 2884 and S462 cells to these 
AKIs. Next, we examined the levels of polyploidy, as 
detected by immunofluorescence (DAPI counterstain) 
or fluorescent cytometry (PI) (Fig. 5C), and senescence, 
as measured through the activity of senescence activated 
beta-galactosidase [21] (Fig. 5D). After 72 hours exposure 
to VX680, but not to MLN8237, we found dramatic 
changes in gross nuclear morphology and the induction 
of senescence in both cell lines (Fig. 5B). Polyploidy was 
significantly more pronounced in S462 cells treated with 
VX680. However, it was only when the dose of MLN8237 
was increased to 1µM that the levels of polyploidy 
observed by cytometry were significantly greater than 
vehicle-treated populations (Fig. 5C).
Mln8237 induces the differentiation of MPnst 
cancer stem-like cells
The levels of polyploidy, apoptosis or senescence 
did not explain the elevated sensitivity of S462 cells to 
MLN8237, so we investigated an alternative cytostatic 
pathway. As the S462 cell-line contains a subset of cancer 
stem-like cells [22] and small-molecule AKIs modify the 
cellular fates of mESCs and induced pluripotent stem cells 
[18, 19], we asked whether treatment with MLN8237 may 
promote the differentiation of these MPNST cancer stem-
like cells. As a first step, we investigated the abilities of 
S462 and 2884 cell-lines to form spheroids when cultured 
under stem cell conditions. While no spheroids were 
identified in 2884 cultures, 5.6 ± 1.2% of S462 cells (168 
±25 of 3,000 seeded) are capable of forming spheroids 
(Fig. 6A). Secondary passage formed significantly more 
spheres (Fig. 6A, labeled passage 1), which is consistent 
with a published report describing self-renewal of sphere-
initiating cells in these cultures [22]. Next, we measured 
AURKA activity and found that p-AURKA, but not total 
AURKA, was elevated in dissociated sphere cells relative 
to parental adherent cells (Fig. 6B). To determine whether 
AURKA activity was necessary for the growth or self-
renewal of MPNST spheres, S462 cells were seeded at 
low densities in the presence of either DMSO or IC-50 
concentrations of MLN8237. By Day 6 (passage 0), sphere 
formation was significantly inhibited in cells treated with 
MLN8237 in comparison to the vehicle alone treated cells 
(166 to 29 spheres in the DMSO and MLN8237 treated 
cells, respectively. p<0.05) (Fig 6C). When we dissociated 
spheres and re-seeded for a second passage, we found that 
the number of spheres formed was significantly reduced in 
the presence of MLN8237, which suggests that AURKA 
activity is necessary for the propagation and self-renewal 
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Figure 6: Inhibition of AurKA by Mln8237 limits self-renewal and induces neuronal differentiation of MPnst 
tumour initiating cells in vitro. A. S462 and 2884 cells were cultured in anchorage independent conditions in neurocult media and 
sphere formation was quantitated after 6 days (passage 0). Spheres were dissociated and cultured for a further 6 days and sphere formation 
was measured again (passage 1). S462 cells form spheres whereas, 2884 cells do not. Representative images on the left, scale bars = 50µm, 
quantitation on the right, error bars = SD, n=3. B. In comparison to adherent S462 cell lysates, sphere-enriched S462 lysates (sphere) 
contain higher levels of auto-activated pAURKA (Thr288) indicating increased AURKA activity in sphere versus adherent S462 cells. 
β-actin serves as a loading control. C. In comparison to DMSO (vehicle) treated controls, prolonged treatment of S462 with 100 nM 
MLN8237 inhibits the propagation (passage 0) and self-renewal (passage 1) of S462 cells cultured as spheres. Quantitation is shown 
below representative images. Scale bars equal 50 µm. Error bars = SD, n=3, *p<0.05, **p<0.001. D. Dissociated sphere-enriched cells at 
passage 4 were fixed and stained for DAPI, nestin, and Tuj1 at day 0 and following 9 days of treatment with MLN8237 (50nM), or DMSO. 
Cells grew in both adherence and sphere phenotypes. While untreated cells maintain expression of nestin through the nine days of culture, 
MLN8237 treated spheres lost nestin expression and are positive for the neuronal marker, Tuj1 instead. Scale bars equal 50µm. E. shTPX2 
and NHP S462 cells were grown in neurocult media. While there were no significant differences in sphere formation in passage 0, TPX2 
knockdown is effecting the self-renewal of these spheres in passage 1, scale bars = 50µm, *p-value< 0.05, error bars = SD, n=3. F. shR1 
and shR2 cells form significantly more spheres in neurocult media than NHP 2884 cells, indicating a role for RHAMM in sphere formation 
by modulating AURKA activity. Scale bars = 50µm, *p-value < 0.05, error bars = SD, n=3.
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of sphere-enriched cancer stem-like cells.
Compared to vehicle treated cultures, spheres 
that formed in the presence of AKI were significantly 
smaller in size and less uniform in shape (Fig. 6C), 
which suggested to us the potential engagement of a 
differentiation pathway. To determine whether treatment 
with MLN8237 can influence the differentiation capacity 
of MPNST cells, we dissociated sphere-enriched cells and 
cultured them on matrigel for nine days in the presence of 
MLN8237 or vehicle control. Dissociated sphere cells then 
grew either as adherent colonies or as attached spheres on 
the matrigel-coated coverslips (Fig. 6D). At seeding and 
after nine days of culture, sphere cells were stained for 
nestin, a type IV intermediate filament protein and marker 
for neuroprogenitor cells, and Tuj1, a neuron-specific 
class III β-tubulin and neural differentiation marker 
[23]. We found that MLN8237 treatment, in relation to 
vehicle alone, modified the cellular fate of sphere cells and 
resulted in the loss of nestin staining, strong expression 
of the neuronal marker Tuj1, and morphological changes 
consistent with neurons, such as neurite-like extensions 
(Fig. 6D). In contrast, DMSO vehicle treated control cells 
maintained a round morphology and nestin expression, 
suggesting that adherent culture alone was not inducing 
their differentiation. 
To investigate whether silencing of TPX2 or HMMR/
RHAMM expression, respectively, is sufficient to prevent 
or endow sphere-forming capacity on MPNST cell-lines, 
we cultured the S462 and 2884 sub-lines under stem cell 
conditions. Stable silencing of TPX2 did not significantly 
alter the propagation of sphere-forming S462 cells in the 
first passage, but may have impacted their self-renewal 
capacity, as indicated by a significant reduction in the 
number of spheres formed during the second passage (Fig. 
6E). However, the stable silencing of HMMR/ RHAMM 
endowed 2884 cells with the capacity to both propagate 
and self-renew as sphere-forming cells (Fig 6F).
dIscussIon
A recent study identified AKI as a viable treatment 
platform for MPNST by first modeling the disease in an 
animal model and then identifying differentially expressed 
genes, including AURKA [5]. In common with their report, 
we identified genomic amplification of AURKA in MPNST 
cell-lines (Fig S2B) and found that robust inhibition of 
growth in vitro followed the silencing of AURKA or the 
treatment of cells with AKI, which also stabilized the 
growth of two primary, human MPNST when grown 
as xenotransplants in animal models. By studying the 
responses of primary human MPNSTs grown in vivo, 
our animal models also contain non-neoplastic cells 
from the human tumour environment, which are critical 
for tumourigenicity [24]. However, we did not identify 
a significant level of endoreduplication downstream of 
AKI except at relatively high doses in vitro and within our 
treated tumours in vivo, which may reflect concomitant 
inhibition of AURKA and AURKB at these dosages. 
Mitotic failure and polyploidy are common cellular 
response to inhibition of AURKB [8] and both MLN8237 
in vivo treatment protocols (20 mg/kg/dose, twice daily or 
30 mg/kg/dose, one daily) result in blood plasma levels 
in excess of 2.5 µM [5, 7], which exceeds the described 
IC-50 against AURKB in cell-based assays [7]. We found, 
however, that a subset of sphere-enriched MPNST cells 
may engage a differentiation program in response to AKI.
To our knowledge, this is the first reported use of 
AKI to drive the differentiation of sphere-enriched cancer 
stem-like cells. We found that AURKA activity is critical 
to the propagation and self-renewal of MPNST sphere cells 
and that these phenotypes were responsive to the silencing 
of regulators for the kinase, such as TPX2 and HMMR/
RHAMM. A strong correlation has been drawn between 
AURKA expression and the maintenance of pluripotency 
in murine embryonic stem cells (mESCs) and, similar to 
our findings, silencing AURKA and treatment with AKI 
was sufficient to drive their differentiation [18]. In mESCs, 
this action of AURKA relies upon the phosphorylation 
and suppression of p53 activity, which may be a TPX2-
independent action as silencing TPX2 did not cause 
significant defects in self-renewal [18]. In our studies, 
however, we find that altering the abundance of either 
TPX2 or HMMR/RHAMM was sufficient to modify the 
growth of MPNST cells as spheres in stem cell cultures. 
Thus, mitotic and non-mitotic roles for AURKA are likely 
to regulate the self-renewal and differentiation of sphere-
enriched cancer stem-like cells, mESC self-renewal [18], 
and reprogramming of somatic cells to produce human 
induced pluripotent stem cells [19]. 
MPNSTs often resist chemotherapies and are prone 
to high rates of disease relapse [2-4]. Here, we find that 
AKI may potentiate the growth and self-renewal of 
MPNST spheroid forming cells, which suggests that 
these drugs may be effective against recurrent disease 
arising from a reservoir of cancer-stem like cells. Indeed, 
inhibitors for aurora kinases are effective against tumour 
cell lines that are refractory to EGFR inhibition [25, 26]. 
These cellular responses to AKI likely rely upon the 
activity of p53, which is often lost in MPNST [27] and is 
critical to the supervision of mitotic failure and tetraploidy 
[28, 29]. AKIs are sufficient to delay G2/M progression 
and the resolution of this delay, be it apoptosis or mitotic 
slippage followed by endoreduplication, relies upon 
the action of p53 [30]. Therefore, concurrent activation 
of the p53 pathway may be an important consideration 
when designing combination therapies for AKIs against 
MPNST. Such an approach has been shown to augment 
the pro-apoptotic actions of AKIs in cell-line models for 
carcinomas [31, 32].
Molecular-targeted single agent therapies often fail 
to demonstrate a significant survival benefit in patient 
populations in part due to our inability to predict tumour 
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responses. So, we aimed to understand and modulate the 
response of MPNST to AKI. Our study shows that the 
responses of MPNST cells in vitro to AKI treatment can 
be significantly altered by the silencing of key regulatory 
molecules. For example, silencing of HMMR/RHAMM 
in 2884 cells, which contain genomic amplification of 
5q32-qter, significantly impacts the sensitivity to AKI 
and endows these cells with the ability to grow in stem 
cell culture, presumably through the release of TPX2 
and activation of AURKA. Consistently, silencing of 
HMMR/RHAMM in breast epithelia cells modulates 
TPX2 location and augments kinase activity [11] while 
attenuation of Xenopus RHAMM (XRHAMM) may 
activate AURKA during anastral spindle assembly [33]. 
Genomic changes that accompany the transition of 
benign neurofibromas to MPNSTs occur at the HMMR/
RHAMM locus [9], the AURKA locus [5](Fig. S2B) and 
chromosome 20q (containing AURKA and TPX2) [9, 15, 
16]. Therefore, these genomic imbalances may endow a 
growth advantage to a subset of human primary MPNSTs 
but also make these tumours exquisitely sensitive to AKI.
Silencing of RHAMM may affect AURKA activity 
in a context or cell-type dependent manner. In multiple 
myeloma cells, RHAMM depletion protects against 
AKI treatment [34]. In Xenopus, XRHAMM depletion 
impaired TPX2 location and anastral assembly [13], which 
should reduce AURKA activity at sites of assembly. We 
believe these apparent contradictory findings are resolved 
by a bimodal model for RHAMM function. RHAMM is 
critical to the correct mitotic location of TPX2 [13, 14] 
and, therefore, its complete loss impairs TPX2-AURKA 
complex formation and attenuates kinase activity. 
However, RHAMM is also a substrate for the active kinase 
that negatively regulates AURKA activation through the 
sequestration of TPX2 [11]. Thus, the hemizygous loss 
of HMMR/RHAMM, or silencing its expression in 2884 
cells with genomic amplification of 5q, may relax this 
negative feedback mechanism, augment kinase activity, 
and sensitize tumour cells to AKI.
Our studies indicate that hemizygous loss of 
HMMR/RHAMM, which occurs in approximately 50% 
of aggressive MPNST [9], may oncogene-addict tumours 
to AURKA activity and sensitize these cancers to AKI. 
This insight may be applied to other tumour subtypes. 
For example, variation in the genomic region surrounding 
HMMR/RHAMM, and the HMMR/RHAMM gene [11], 
modifies the risk to develop breast cancer in carriers of 
germline BRCA1 mutations [35]. These carriers often 
develop breast tumours that do not express estrogen 
receptor, progesterone receptor or human epidermal 
growth factor receptor (HER-2), resemble basal epithelia 
by gene expression profiles (i.e. basal subtype), and are 
refractory to anti-estrogen therapy, hormone therapy, and 
targeted therapies directed against HER-2 [36]. The loss 
of 5qter, a genomic region surrounding HMMR/RHAMM, 
is a frequent event in basal subtype breast cancer [37], 
and this genomic loss associates with an increase in the 
expression of AURKA in trans [38]. Thus, genomic loss 
of HMMR/RHAMM may indicate a subset of tumours that 
are reliant upon AURKA and highly susceptible to AKI.
In summary, our findings and those of Patel and 
colleagues [5] highlight AURKA as a new therapeutic 
target for MPNST. For the first time, we describe a 
pro-differentiation effect for AKI on a subset of sphere-
enriched cancer stem-like cells and demonstrate that 
copy number alteration of regulatory gene-products, like 
HMMR/RHAMM and TPX2, can significantly impact the 
tumour cellular responses to these emerging therapies.
MAterIAls And MetHods 
In vivo animal models 
Four-month-old male NOD/SCID mice were 
anesthetized with isofluorane and orthotopically implanted 
with 1 mm3 piece of explant tumour in both legs, near 
the sciatic nerve (Castellsagué et al. manuscript under 
preparation). Tumour volume was calculated at V= 
(W2*L (π/6)), where L is the longest diameter and W is 
the width. Mice were randomly assigned to treatment 
or control groups. Dosage of MLN8237 in mice was 
previously determined (31). Mice were treated by 
gavage once daily with 30mg/kg MLN8237 or vehicle 
(10% 2-hydroxypropyl-β-cyclodextrin and 1% sodium 
bicarbonate) for 28 days. Tumours were measured every 
3 days. At the end of the treatment period, mice were 
euthanized and harvested tumours were fixed in formalin.
Adherent culture and culture as spheres 
Cell-lines were obtained from Drs. VF Mautner 
and L Kluwe (University Hospital Eppendorf, Germany) 
or the ATCC and were cultured as recommended. Unless 
noted otherwise, cells were seeded at 1.0 x 104 (S462 cell-
line) or 3.0 x 104 (2884 and 2885 cell-lines) cells/well in 
24-well culture plates and allowed to adhere for 24 hours 
prior to the denoted treatment. These seeding densities 
resulted in equivalent growth kinetics for S462 and 2884 
cells. The culture of S462 spheres followed the protocol 
in [22]. 
sirnA and small molecule reagents
siRNA (Qiagen, Table S1) were transfected at 
10 pmol/well using Lipofectamine2000™ according 
to manufacturer’s protocols (Invitrogen). AURKA 
knockdown was confirmed at 48 hours post transfection. 
Small-molecule AKIs were dissolved and diluted in 
DMSO/DMEM and included the pan-aurora inhibitors 
Oncotarget 2013; 4: 80-9391www.impactjournals.com/oncotarget
C1368 (Sigma) and VX680 (Selleck Chemicals), and the 
AURKA specific inhibitor MLN8237 (Selleck Chemicals). 
lentivirus mediated shrnA knockdown and 
generation of sub-lines
Lentivirus packaging, envelope and control non-
hairpin (NHP) pLKO.1 plasmids (Addgene) were used 
with shRNA against RHAMM and TPX2 (Sigma) as 
described in [11] (Table S1). Transfected cells were 
selected with 0.5µg/ml puromycin (GIBCO) and 
maintained with 0.3µg/ml puromycin. 
Immunofluorescence, immunohistochemistry, and 
immunoblot analyses 
Antibodies were sourced as follows: RHAMM 
(Epitomics), TPX2 (Novus), nestin (Covance), Tuj1 
(Covance), β-actin (Sigma), AURKA, phospho (p)-
AURKA (Thr288), p-histone H3 (Ser10), and caspase 9 
(Cell Signalling). The p-RHAMM (Thr703) polyclonal 
antibody is characterized in [11].
Cell-lines were fixed and permeabilized in methanol. 
Antibodies were diluted in PBS-0.1% Tween and 3% BSA 
(Sigma). Coverslips were mounted in 90% glycerol/PBS 
with DAPI (Invitrogen) and images were acquired and 
analyzed using an Olympus FV10i confocal microscope.
For immunofluorescence of spheres, coverslips were 
coated with 2% geltrex (Invitrogen) in Neurocult media 
(StemCell Technologies) before cells were plated. Cells 
were fixed with 4% PFA and then stained.
Immunohistochemistry on paraffin sections 
was done as in [11]. Secondary antibody staining 
was done with the relevant antibodies for 30 minutes 
at room temperature. Staining was visualized by 
3,3-diaminobenzidine, with Hematoxylin as a counter-
stain.
Western blot analyses were performed on lysates 
collected from sub-confluent MPNST cells lysed in 
modified RIPA buffer, as described [39]. Levels of protein 
were detected and quantified with the Odyssey infra-red 
imaging system (LI-COR) using IRDye 800- or IRDye 
680-conjugated secondary antibodies (Rockland) or 
through chemiluminescence detection of HRP-conjugated 
antibodies (Sigma).
Genomic and reverse-transcriptase Pcr and real-
time Pcr
Genomic DNA was extracted with the DNeasy 
extraction kit (Qiagen) and preparations were measured 
with a NanoDrop (Thermo-Fisher). For real-time, genomic 
PCR, reactions were run in triplicate with an Applied 
Biosystems 7000 series machine (Invitrogen). RNA was 
extracted using the RNeasy kit (Qiagen), quantified with 
NanoDrop and converted to cDNA using AccessQuick 
(VWR) as per manufacturer’s protocols. For primers 
and PCR conditions see Table S1. Results were analyzed 
using the ∆∆Ct method. Expression of transcript/gene was 
normalized to TATA box binding protein levels, which was 
then normalized to levels of transcript/gene in 2885 cells. 
Array comparative genomic hybridization 
(a-cGH) 
Genomic DNA was isolated using the Gentra 
Puregene Cell Kit (Qiagen). Purified DNA was 
digested with Bovine DNase I (Ambion). Test and 
control samples were labelled with Alexa5 and Alexa3 
dyes respectively using the BioPrime Total Genomic 
Labeling Kit (Invitrogen). Labeled samples were 
competitively hybridized to 2 x 400k Human CGH 
Arrays (Agilent Technologies) as recommended by the 
manufacturer. Copy number estimates were extracted 
from the microarray image files using Feature Extraction 
10.5 (Agilent) and the data were analyzed in Agilent 
Genomic Workbench 6.5 (Agilent) after centralization 
and fuzzy zero normalization matrixes were applied. 
Copy number abnormalities were identified using the 
ADM-2 algorithm with a threshold setting of 5.5 and 
regions were only considered significant if they were 
defined by a minimum of 3 probes and the average log2 
value exceeded a threshold of 0.2 (grey shaded regions).
cell based assays
For cell viability assays, MPNST cell-lines 
were plated and after 24 hours were treated with 
carrier alone (0.1% DMSO) or AKIs at indicated 
concentrations. Viability was quantified after 72 hours 
by addition of 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTT, Invitrogen) as recommended by the 
manufacturer. Each condition was done in triplicate and 
repeated three times. For growth curves, MTT assays were 
conducted at 24, 48, 72 and 96 hours after plating.
For nuclear content analysis by FACS, cells were 
harvested, fixed and stained as in [40] and analyzed 
with FACS Calibur and CellQuestPro software (BD 
Biosciences), respectively. For polyploidy analysis, 
AKI treated cells were stained with DAPI. Nuclei area 
was measured using Image J software. Annexin V (BD 
Biosciences) staining followed manufacturer’s protocol. 
Images were collected with a High Content Analyzer 
(ArrayScan VTI, Cellomics).
Cellular senescence was measured by detection of 
senescence-activated β-Galactosidase activity. Cells were 
plated, treated with AKIs for 72 hours, fixed and stained 
as described in [21]. 
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statistics
Statistical significance was evaluated by unpaired 
two-tailed Student’s t-tests with p>0.05. Two way ANOVA 
was used to determine significance between treatments for 
in vivo tumour volumes using GraphPad Prism.
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